Why Is Novavax (NVAX) Stock Down -8.36% Today?
Key Takeaways
- Novavax shares fell 8.36% on Tuesday, giving back a large portion of the prior session's surge.
- The pullback follows a 20% rally on Monday sparked by a suspected plague case at a Russian research institute.
- Health officials from Rospotrebnadzor and the World Health Organization downplayed the public-health risk, removing the premise behind the speculative bid.
- The move is concentrated in the most speculative corner of the vaccine group, reflecting profit-taking and a partial short-squeeze unwind.
- Traders are watching for any further official statements on the outbreak, plus Novavax's upcoming earnings report.
Opening Summary
NVAX, the ticker for Novavax, Inc., a biotechnology company best known for its protein-based COVID-19 vaccine Nuvaxovid and its Matrix-M adjuvant technology, pulled back sharply in Tuesday's session. The stock was trading around $11.51, down 8.36% from Monday's closing price of $12.56. The decline reversed a dramatic move: shares had surged more than 20% in the previous session as vaccine stocks rallied on reports of a suspected pneumonic plague case at a laboratory in Siberia. As health authorities characterized the public risk as low, the speculative bid that had lifted NVAX quickly unwound.
A Plague Scare That Lifted the Stock Is Now Deflating
The catalyst for Monday's surge was a headline-driven trade, not a fundamental change in Novavax's business. Reports that a 28-year-old technician died at the Irkutsk Research Anti-Plague Institute in Siberia fueled speculation that heightened biodefense preparedness could lead to government vaccine purchases. Vaccine and biodefense names across the sector rallied, and NVAX—a smaller, more speculative developer—drew the most direct retail and momentum-driven interest.
That narrative began to unwind almost immediately. Rospotrebnadzor, the Russian public-health agency, said samples contained no microorganisms associated with the worker's professional duties and described the regional epidemiological situation as stable. The World Health Organization separately said the risk to the general population appeared low. With the purchase scenario deflated, the air came out of the trade.
A Trade Without a Fundamental Anchor
One reason the reversal has been swift is that Novavax has no plague vaccine and no direct product line tied to the pathogen in question—a bacterium, rather than the viruses its protein-based platform targets. The Monday rally priced in emergency government orders that the company's pipeline does not address. Analysts noted that the surge was driven largely by market sentiment and short covering rather than any new business opportunity.
Novavax's own fundamental story remains centered on partnerships. It collects royalties on partner sales of its updated Nuvaxovid vaccine, with Sanofi and Takeda having secured approvals across the United States, European Union, and Japan ahead of the 2026–2027 season, and a $75 million manufacturing technology-transfer payment expected in the fourth quarter. Those fundamentals were unchanged by the outbreak headlines, leaving the speculative portion of the move vulnerable to reversal.
Short Squeeze Dynamics and Profit-Taking
Monday's spike was amplified by elevated short interest—reported at roughly 30% of the float heading into the move. The sudden surge in volume forced short sellers to cover, adding fuel to the rally. On Tuesday, that dynamic reversed into profit-taking as momentum faded and the news catalyst lost credibility. The unwind in NVAX was notably more severe than in peers, underscoring how much of the prior gain was tied to speculative positioning rather than sustained buying.
Market Context and Trading Activity
The pullback in NVAX diverged from some vaccine peers, reflecting how concentrated the prior move had been in the most speculative names. MRNA (Moderna) held firmer on the day, a sign the market was distinguishing a direct vaccine seller from a royalty-focused developer. Monday's trading volume in NVAX ran far above its daily average, and Tuesday's decline came on continued elevated activity as traders repositioned. The stock, which had surged to near its 52-week high of $13.38, pulled back after testing that upper range.
What Comes Next for NVAX
Looking ahead, NVAX faces a series of company-specific catalysts beyond the fading outbreak story. The company is expected to report its next quarterly results soon, with analysts projecting a narrower year-over-year loss but a sharp decline in revenue as its business shifts toward royalty collection rather than direct sales. Any further statement from Rospotrebnadzor or the World Health Organization on the Siberian case could revive or further extinguish the vaccine trade. Traders will also watch whether Monday's breakout can hold on a weekly basis or whether the stock reverts toward the range it traded in for much of the prior months. Given the company's persistent losses and negative cash flow, sentiment remains highly sensitive to pipeline and partnership headlines.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from hundreds of available strategies covering thousands of tickers. Only the strongest performers under current market conditions are featured, with bots varying by strategy, timeframe, performance metrics, and the symbols they trade. Explore the page to see which automated strategies are currently leading the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
NVAX sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for NVAX moved above the 200-day moving average on September 24, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 21, 2026. You may want to consider a long position or call options on NVAX as a result. In 66 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for NVAX just turned positive on October 05, 2026. Looking at past instances where NVAX's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Following a +1.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVAX advanced for three days, in 183 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
The Aroon Indicator entered an Uptrend today. In 93 of 116 cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 49 cases where NVAX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
NVAX broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.467) is normal, around the industry mean (26.780). P/E Ratio (3.140) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (3.759) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in development of novel recombinant vaccines
Industry Biotechnology
Advertisement